NABIL SIDDIQI: Open Payments
NPI 1982996484 · LONGWOOD, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,236 in 55 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $743 · 2025 $1,236
Food & beverage: $1,236
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $282 |
| ABBVIE INC. | 10 | $157 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $157 |
| Neurocrine BioSciences, Inc. | 5 | $129 |
| E.R. Squibb & Sons, L.L.C. | 6 | $114 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Lundbeck LLC | 3 | $69 |
| Janssen Pharmaceuticals, Inc | 3 | $66 |
| Alkermes, Inc. | 3 | $56 |
| Bausch Health US, LLC | 3 | $54 |
Products named: REXULTI, VRAYLAR, CAPLYTA, ABILIFY ASIMTUFII, INGREZZA, COBENFY, FANAPT, LYBALVI.
Industry payments across FL — which companies pay providers there.
